中华肿瘤杂志最新文献

{"title":"[Prognostic analysis of double primary breast cancer and endometrial cancer patients based on SEER database].","authors":"S Y Shi, X C Jia, Y L Yang, N Sun, Y Zhang, W Wang","doi":"10.3760/cma.j.cn112152-20231006-00164","DOIUrl":"10.3760/cma.j.cn112152-20231006-00164","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the survival outcomes and prognostic factors of patients with double primary breast cancer (BC) and endometrial cancer (EC). <b>Methods:</b> A retrospective cohort study was conducted using data for the period 1992-2018 from the Surveillance, Epidemiology, and End Results (SEER) database. There were 3 465 patients with BC as the first primary cancer (BC-EC group) and 2 804 patients with EC as the first primary cancer (EC-BC group). Kaplan-Meier analysis and cumulative incidence function were used to estimate overall mortality, breast cancer-specific mortality, and endometrial cancer-specific mortality, respectively. Cox regression and Fine-Gray regression were used to analyze the prognostic factors of overall mortality, breast cancer-specific mortality, and endometrial cancer-specific mortality, respectively. <b>Results:</b> During a median follow-up of 160 months, 1 616 deaths occurred in the BC-EC group, with EC being the leading cause of death (37.69%); 994 deaths occurred in the EC-BC group, with BC being the leading cause of death (28.77%). Cox regression identified patients with older ages at first primary cancer diagnosis (54-61 years: <i>HR</i>=1.46, 95% <i>CI:</i> 1.26-1.69; 62-68 years: <i>HR</i>=2.64, 95% <i>CI</i>: 2.29-3.03; ≥69 years: <i>HR</i>=4.89, 95% <i>CI</i>: 4.27-5.60), shorter time interval between the diagnoses (0-5 months: <i>HR</i>=6.13, 95% <i>CI</i>: 5.21-7.21; 6-23 months: <i>HR</i>=5.69, 95% <i>CI</i>: 4.95-6.55; 24-59 months: <i>HR</i>=3.44, 95% <i>CI</i>: 3.04-3.89; 60-119 months: <i>HR</i>=2.32, 95% <i>CI</i>: 2.07-2.59), mixed ductal-lobular BC (<i>HR</i>=1.29, 95% <i>CI</i>: 1.11-1.48), endometrial mixed cell adenocarcinoma (<i>HR</i>=1.23, 95% <i>CI</i>: 1.01-1.50), advanced tumor grade (grade Ⅱ BC: <i>HR</i>=1.13, 95% <i>CI</i>: 1.01-1.27; grade Ⅲ BC: <i>HR</i>=1.24, 95% <i>CI</i>: 1.10-1.41; grade Ⅱ EC: <i>HR</i>=1.19, 95% <i>CI</i>: 1.06-1.33; grade Ⅲ EC: <i>HR</i>=1.68, 95% <i>CI</i>: 1.48-1.90), advanced tumor stage of the two cancers (distant BC: <i>HR</i>=3.14, 95% <i>CI</i>: 2.50-3.94; regional EC: <i>HR</i>=1.53, 95% <i>CI</i>: 1.36-1.71; distant EC: <i>HR</i>=3.00, 95% <i>CI</i>: 2.59-3.47) had increased risk of overall mortality. Fine-Gray regression showed that compared with BC-EC patients, EC-BC patients had a higher risk of breast cancer-specific mortality [sub-distribution hazard ratio (s<i>HR</i>=1.24, 95% <i>CI</i>: 1.04-1.47], but a lower risk of endometrial cancer-specific mortality (s<i>HR</i>=0.37, 95% <i>CI</i>: 0.30-0.46). Older ages at first cancer diagnosis, shorter intervals between the diagnoses, negative ER and PR status, and advanced BC grades/stages were associated with increased breast cancer-specific mortality (<i>P</i>＜0.05). Similarly, older ages, shorter intervals, endometrial serous carcinoma/mixed cell adenocarcinoma, and advanced EC grades/stages correlated with elevated endometrial cancer-specific mortality (<i>P</i>＜0.05). <b>Conclusi","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 8","pages":"734-744"},"PeriodicalIF":0.0,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144856647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Utidelone induces apoptosis and autophagy in small cell lung cancer cells through the ROS/AMPK signaling pathway].","authors":"X Q Mu, C N Yu, Y Q Zhao, X F Hu, H B Wu","doi":"10.3760/cma.j.cn112152-20240623-00263","DOIUrl":"10.3760/cma.j.cn112152-20240623-00263","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effects and underlying molecular mechanisms of Utidelone (UTD1) in small cell lung cancer (SCLC). <b>Methods:</b> The study utilized small cell lung cancer H446 and H1048 cell lines along with animal models. Cell proliferation, cell cycle progression, apoptosis, autophagy, and related activities following UTD1 treatment were assessed using Cell Counting Kit-8 (CCK-8), flow cytometry, immunofluorescence staining, reactive oxygen species (ROS) generation assay, and Western blot analysis. The involvement of the ROS/adenosine monophosphate-activated protein kinase (AMPK) signaling pathway was also examined. Data analysis was performed using GraphPad Prism version 8 software. <b>Results:</b> UTD1 inhibited the viability of H446 and H1048 cells in a dose- and time-dependent manner. The half inhibitory concentrations (IC₅₀) of UTD1 for H446 and H1048 cells were 0.675 and 0.439 μg/ml, respectively. The proportion of cells in the G₂/M phase for H446 and H1048 cells in the UTD1 group at 6 h, 12 h, and 24 h was [(53.86±4.54)%, (68.59±5.49)%, (60.89±3.26)%] and [(46.83±2.20)%, (60.67±3.44)%, (57.88±5.11)%], which were significantly higher than that in the control group, except for the proportion of H1048 cells at 6 h [(38.99±2.60)% vs. (40.73±2.50)%, <i>P</i>＜0.05]. The apoptosis rates were [(23.57±0.12)%, (35.79±1.59)%, and (46.15±4.57)%] for H446 cells and [(23.05±2.70)%, (37.73±2.97)%, and (43.39±3.31)% for H1048 cells], all of which were significantly higher than those in the control group [(6.44±0.96)%, (6.31±0.75)%, respectively; all <i>P</i>＜0.05]. The number of LC3 fluorescent spots was [(56±11), (69±8), and (66±8)] for H446 cells and [(39±7), (56±12), and (50±11)] for H1048 cells, both significantly higher than those in the control group [(13±6) and (12±5), respectively; both <i>P</i>＜0.05]. The relative fluorescence intensity of ROS was 2.54±0.48, 2.85±0.68, and 5.03±0.72 for H446 cells and 2.26±0.51, 4.17±0.35, and 4.66±0.51 for H1048 cells, which were also significantly higher than those in the control group (<i>P</i>＜0.05). The expression levels of cyclin B1, cyclin A2, and P21 of H446 cells in the three time points were [(0.63±0.07, 0.33±0.05, 0.23±0.04), (0.68±0.08, 0.46±0.03, 0.27±0.06), and (0.64±0.03, 0.32±0.05, 0.22±0.03), respectively], all significantly lower compared to the control group (<i>P</i>＜0.05). The apoptosis rates of H446 and H1048 cells in the UTD1+Z-VAD-FMK group were (19.97±3.19)% and (17.68±3.14)%, both lower than those in the UTD1 group [(40.73±3.35)% and (39.82±2.45)%, respectively; all <i>P</i>＜0.05]. The absorbance values of H446 and H1048 cells in the UTD1+3-MA group were significantly higher than those in the UTD1 group at 6h, 12h, and 24h (all <i>P</i>＜0.05). The levels of p-AMPKα/AMPKα, LC3-II expression, and the percentage of apoptotic cells in the H446 and H1048 cells of the UTD1+NAC group were [(1.33±0.09, 1.33±0.11), (1.49±0.16, 1.55±0.05), (17.24","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 8","pages":"703-714"},"PeriodicalIF":0.0,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144856649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of discordant results between multiplex fluorescence PCR-capillary electrophoresis for microsatellite instability (MSI) detection and immunohistochemistry (IHC) for mismatch repair (MMR) protein expression in gastrointestinal adenocarcinoma].","authors":"Y J Gu, H M Xu, Q Y Li, F Yuan, L Dong, C F Wang","doi":"10.3760/cma.j.cn112152-20241031-00469","DOIUrl":"10.3760/cma.j.cn112152-20241031-00469","url":null,"abstract":"<p><p><b>Objective:</b> This study investigated the underlying causes of discordance between multiplex fluorescence polymerase chain reaction (PCR)-capillary electrophoresis in determining MSI and immunohistochemistry (IHC) for mismatch repair (MMR) protein evaluation in gastrointestinal adenocarcinomas, aiming to improve interpretation accuracy and guide clinical precision treatment strategies. <b>Methods:</b> A retrospective analysis was conducted on 511 surgically resected or biopsied specimens (161 gastric adenocarcinomas and 350 colorectal adenocarcinomas) diagnosed at the Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January to June 2024. MMR protein expression of tumors was evaluated by IHC, while MSI status was assessed using the 2B3D National Cancer Institute (NCI) Panel through multiplex fluorescence PCR-capillary electrophoresis on tumor DNA and matched normal DNA. The concordance between the two methods was analyzed, and factors contributing to the discordance were investigated. Cases with unstable dinucleotide loci only in the 2B3D NCI Panel, focal MMR protein loss, or unexplained discrepancies underwent validation using the non-NCI Panel through multiplex fluorescence PCR-capillary electrophoresis markers or next-generation sequencing (NGS). <b>Results:</b> In the 511 gastrointestinal adenocarcinomas, the results of the two methods were discordant in 15 cases (2.9%), with a significantly higher discordantrate in gastric cancers (7.5%, 12/161) compared to colorectal cancers (0.9%, 3/350; <i>P</i>＜0.001). Key contributors to the discordance included: sampling limitations (6 cases), 2B3D NCI Panel design constraints (3 cases),tumor heterogeneity (3 cases),isolated MSH6 deficiency (1 case),and unexplained discrepancies (2 cases).Validation studies demonstrated that cases with dinucleotide-only instability showed concordance with IHC after using the non-NCI Panel through multiplex fluorescence PCR-capillary electrophoresis and NGS verifications. Specimens with focal MMR protein loss and unexplained discrepancies aligned with initial PCR results upon NGS validation. Unexplained cases harbored Kirsten rat sarcoma class Ⅰ variants and multiple class Ⅱ genetic alterations. <b>Conclusions:</b> Colorectal adenocarcinoma demonstrated higher concordance between PCR-capillary electrophoresis and IHC than gastric adenocarcinoma.Discordant results require systematic evaluation including technical review, specimen quality control, and supplemental NGS analysis to resolve discrepancies.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 8","pages":"715-725"},"PeriodicalIF":0.0,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144856621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application of CT guided percutaneous interstitial brachytherapy in the treatment of recurrent cervical cancer with isolated lesions in the radiated field].","authors":"Y M Ma, W L Xia, D B Wang, H Wu, M C Zhang, S X Cheng","doi":"10.3760/cma.j.cn112152-20241029-00467","DOIUrl":"10.3760/cma.j.cn112152-20241029-00467","url":null,"abstract":"<p><p><b>Objective:</b> To explore the safety and efficacy of computed tomography (CT) guided percutaneous interstitial brachytherapy in the treatment of recurrent cervical cancer with isolated lesions in the radiated field. <b>Methods:</b> A retrospective analysis was conducted on the clinical data of 30 patients with recurrent cervical cancer with isolated lesions in the radiated field who underwent CT guided percutaneous interstitial implantation for close range radiation treatment at Zhengzhou University Affiliated Cancer Hospital from March 2023 to August 2024. Under local anesthesia, a needle was implanted into the recurrent tumor in the pelvic or abdominal wall of the patients percutaneously guided by CT. The target area was delineated to ensure full dose coverage. The prescribed dose for high-risk clinical target areas was 600 cGy/time, once a week, followed by close range radiotherapy. The number of implanted needles were recorded, and the target area, radiation dose, and other parameters were evaluated through dose volume parameter maps. The degree of lesion shrinkage and the occurrence of complications during and after treatment were observed. <b>Results:</b> 30 patients underwent a total of 72 rounds of brachytherapy with implantation, with a technical success rate of 100% (72/72). 20 cases received 2 treatments, 8 cases received 3 treatments, and 2 cases received 4 treatments; 4 cases used 1needle, 20 cases used 2 needles, 4 cases used 3 needles, and 2 cases used 4 needles. The high-risk clinical target dose D₉₀ was (718.17±222.61) cGy. The average dose D_2cc of 2 cm³ surrounding the bladder, rectum, sigmoid colon, and small intestine was (168.29±53.80) cGy, (178.87±105.38) cGy, (136.05±78.06) cGy, and (288.91±117.49) cGy, respectively. The median follow-up time was 11 months. Among the 30 patients, there were 12 cases of complete remission,14 cases of partial remission, 3 cases of stable disease, and 1 case of disease progression, with an objective remission rate of 86.7%. None of the patients experienced significant bleeding or pain during treatment. After treatment, 3 patients with recurrent lymph nodes near the rectum developed grade 1 radiation proctitis, which was remitted after treatment. No significant complications were observed in the remaining patients. <b>Conclusion:</b> CT guided percutaneous brachytherapy is safe and feasible for the recurrence of single lesions in the radiated field of cervical cancer.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 8","pages":"745-749"},"PeriodicalIF":0.0,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144856623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Influence of varying frequency parameters in high-frequency oscillatory ventilation on the therapeutic efficacy of heavy ion radiotherapy in patients with thoracic and abdominal neoplasms: a prospective randomized controlled trial].","authors":"R H Song, Y Wang","doi":"10.3760/cma.j.cn112152-20250403-00147","DOIUrl":"10.3760/cma.j.cn112152-20250403-00147","url":null,"abstract":"<p><p><b>Objective:</b> To explore the effects and prognosis of heavy ion therapy for thoracic and abdominal malignant tumors under different frequency settings of high-frequency oscillatory breathing control. <b>Methods:</b> A prospective randomized controlled trial was conducted on 45 patients with thoracic and abdominal malignant tumors who received heavy ion therapy under high-frequency oscillatory ventilation (HFOV) control at Gansu Wuwei Tumour Hospital from January 2023 to December 2024. The patients were randomly divided into three groups by block randomization, with 15 patients in each group, and they received different HFOV frequency settings (6 Hz, 7 Hz and 8 Hz, i.e., 360 breaths/min, 420 breaths/min and 480 breaths/min), while other parameters were kept constant (oxygen concentration: 40%, mean airway pressure: 10 cmH₂O, amplitude: 6cm). The arterial blood gas, transcutaneous carbon dioxide partial pressure/transcutaneous oxygen partial pressure (TcPCO₂/TcPO₂), duration of HFOV ventilation, duration of invasive mechanical ventilation, length of hospital stay and complications of the patients under different frequency settings were analyzed. <b>Results:</b> Before and after treatment, there was no statistically significant difference in arterial blood gas parameters (PaCO₂, PaO₂), oxygenation index, blood lactate, bicarbonate ion) among the 6 Hz,7 Hz and 8 Hz HFOV frequency groups (all <i>P</i>＞0.05). At 30 minutes, 60 minutes, 120 minutes of treatment and at extubation, there was no statistically significant difference in TcPCO₂, TcPO₂, SpO₂ and heart rate among the 6 Hz, 7 Hz and 8 Hz HFOV frequency groups (all <i>P</i>＞0.05). The HFOV duration of the 6 Hz, 7 Hz and 8 Hz HFOV frequency groups was (131.7±8.4) minutes, (125.3±6.9) minutes and (115.7±10.5) minutes, respectively; the duration of invasive mechanical ventilation was (212.3±21.2) minutes, (190.7±14.8) minutes and (199.3±18.4) minutes, respectively; the tumor shrinkage rate was (53.1±6.1)%, (64.7±5.1)% and (63.0±6.2)%, respectively; and the hospital stay was (22.7±2.9) days, (22.3±3.1) days and (20.8±3.3) days, respectively. There was no statistically significant difference among the groups (all <i>P</i>＞0.05). Only one patient developed reversible hypercapnia, which returned to the normal range within 30 minutes after adjusting the invasive ventilator parameters. No treatment-related adverse events such as hypoxemia, radiation pneumonitis, or hemodynamic instability occurred in any of the subjects. <b>Conclusions:</b> HFOV management under heavy ion therapy for thoracoabdominal malignancies shows no significant changes in arterial blood gas analysis before and after treatment at different frequencies (6 Hz, 7 Hz, 8 Hz). Continuous monitoring of transcutaneous TcPCO₂/TcPO₂ is stable. The treatment process is safe, with few complications and good results.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"679-685"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on combined screening for common cancers(2025 edition)].","authors":"K X Chen, W Q Chen, Y B Huang, Z Y Lyu, F F Song, C F Xia, Y J Xu, L Yang, C Sheng, Y C Zhang, P Wang, Y M Zhang, Y T Ji, J J Li, W X Li, J Wu, Q Y Jin, F J Song","doi":"10.3760/cma.j.cn112152-20250604-00255","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20250604-00255","url":null,"abstract":"<p><p>Malignant tumors (commonly referred to as cancer) represent a major global public health challenge and contribute significantly to the worldwide disease burden. Early screening plays a critical role in improving detection rates, enabling timely intervention, and enhancing patient survival rates. However, current cancer screening guidelines primarily focus on site-specific screening, which may not fully address the need for comprehensive early detection. A scientifically rational, multi-cancer screening approach offers several advantages: it optimizes the use of biological samples, reduces time costs for participants, enhances the efficiency and comprehensiveness of screening, and minimizes overall expenses. Such an approach also facilitates the rational allocation of healthcare resources, ultimately helping to reduce the societal burden of cancer. To address this need, the Cancer Epidemiology Committee of the Chinese Anti-Cancer Association has developed the Expert Consensus on Combined Screening for Common Cancers in China. This consensus integrates multidisciplinary expertise and synthesizes the latest domestic and international researches on cancer screening, early detection, and treatment for prevalent malignancies. Drawing upon China's unique demographic and healthcare context, as well as practical screening experiences, the consensus provides evidence-based recommendations on target populations, screening technologies, and procedural workflows for multi-cancer screening. These guidelines align with the principles and methodologies established by the World Health Organization (WHO), aiming to enhance the effectiveness of combined cancer screening in China, improve early detection rates, and provide a scientific foundation for national cancer prevention and control strategies.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"533-557"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression of SIPA1 in colorectal cancer and its impact on its biological behavior].","authors":"N Z Wang, L Zhang, J Chen, H Chen, R C Wang, C H Lu, Y F Ji","doi":"10.3760/cma.j.cn112152-20240812-00338","DOIUrl":"https://doi.org/10.3760/cma.j.cn112152-20240812-00338","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objectives:&lt;/b&gt; To investigate the expression of signal-induced proliferation-associated 1 (SIPA1) in colorectal cancer tissues and its relationship with patient prognosis. To explore the effects of SIPA1 on proliferation and migration abilities, as well as the possible molecular mechanisms. &lt;b&gt;Methods:&lt;/b&gt; Using The Cancer Genome Atlas (TCGA) database to analyze the differential expression of SIPA1 and conduct survival analysis. Then, plotting receiver operating characteristic curve (ROC) and prognosis calibration curve analysis to assess the predictive capability and accuracy of SIPA1 for patient prognosis. Subsequently, verifying the expression levels of SIPA1 in tumor tissues and adjacent normal tissues using immunohistochemistry (IHC) and western blot (WB) assays(from March 1, 2023, to May 1, 2024, pathological specimens of five colorectal cancer patients were selected from the tissue bank of affiliated hospital of Nantong University. tissue microarrays were constructed using both cancerous tissues and adjacent normal tissues), and exploring the correlation between SIPA1 and clinical pathological parameters. Next, establishing SIPA1 stable knockdown cell lines in colorectal cancer cell lines DLD1 and HCT116, and assessing the biological behavior changes of tumor cells after SIPA1 knockdown through cell proliferation, invasion, and migration experiments. Validating the impact of SIPA1 on colorectal cancer cell proliferation &lt;i&gt;in vivo&lt;/i&gt; through subcutaneous xenograft experiments in nude mice. Exploring the potential pro-tumor mechanisms of SIPA1 through pathway enrichment analysis, and confirming these using WB experiments. The proliferation, invasion and migration of tumor cells were detected after adding PI3K activator. Lastly, conducting correlation analysis between SIPA1 and immune checkpoint, as well as the association with immune cells in the tumor microenvironment. &lt;b&gt;Results:&lt;/b&gt; Differential analysis showed that mRNA expression of SIPA1 in colorectal cancer tissues was significantly higher than that in adjacent normal tissues (&lt;i&gt;P&lt;/i&gt;＜0.05). Prognostic analysis indicated that patients with high expression of SIPA1 had poor overall survival (&lt;i&gt;P&lt;/i&gt;＜0.001), and the expression level of SIPA1was correlated with lymph node invasion (&lt;i&gt;P&lt;/i&gt;＜0.001) and N stage (&lt;i&gt;P&lt;/i&gt;＜0.05). ROC curve and prognosis calibration curve suggest that SIPA1 can effectively predict five-year survival rate of patients (AUC=0.7), and the predictive performance of the model is relatively accurate (&lt;i&gt;P&lt;/i&gt;＜0.001). WB experiments showed a significant increase in the expression level of SIPA1 protein in colorectal cancer specimens (&lt;i&gt;P&lt;/i&gt;＜0.001). Immunohistochemistry results indicated higher staining scores of SIPA1 in tumor tissues. &lt;i&gt;In vitro&lt;/i&gt; experiments demonstrated that SIPA1 knockdown significantly inhibited the proliferation, invasion, and migration capabilities of colorectal cancer cells. In DLD1 and HCT116 cells, the SIPA1-knockdown gro","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"657-668"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correlation between neutrophil extracellular traps and clinicopathological characteristics and prognosis of EGFR wild-type lung adenocarcinoma].","authors":"X X Zhang, R Zhang, Y W Guo, L Y Wu, J J Ma, X X Li","doi":"10.3760/cma.j.cn112152-20240929-00423","DOIUrl":"10.3760/cma.j.cn112152-20240929-00423","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the predictive value of neutrophil extracellular traps (NETs) on the prognosis of patients with epidermal growth factor receptor (EGFR) wild-type lung adenocarcinoma. <b>Methods:</b> A total of 132 surgical paraffin specimens of EGFR wild-type lung adenocarcinoma diagnosed at the Tumor Hospital Affiliated to Xinjiang Medical University from January 2016 to December 2023 and 12 pairs of cancer and paracancerous fresh tissues from patients with EGFR wild-type lung adenocarcinoma diagnosed in March-July 2024 were collected with their clinical information. Western blotting and immunofluorescence were used to detect the expression levels of citrullinated histone H3 (CitH3) and myeloperoxidase (MPO) in cancerous and paraneoplastic tissues. Immunohistochemistry was used to detect the infiltration of PD-L1, CD4⁺ T cells and CD8⁺ T cells in the tumors. The clinical and prognostic correlations between NETs and EGFR wild-type lung adenocarcinoma patients were analyzed. <b>Results:</b> The expression of MPO (<i>P</i>＜0.001) and CitH3 (<i>P</i>=0.009) was significantly increased in the tumors compared with the paracancerous tissues. The rate of high expression of NETs in cancer tissues was higher in patients with EGFR wild-type lung adenocarcinoma who were in stage Ⅲ and Ⅳ, with lymph node metastasis, distant metastasis, pleural invasion, high expression of Ki-67, low expression of CD8⁺ T, and lowered lymphocyte counts when compared to paraneoplastic tissues (<i>P</i>＜0.05). Patients were stratified based on TNM stage Ⅱb for prognostic analysis. Kaplan-Meier univariate analysis showed that the median overall survival (OS) (stage Ⅰ to Ⅱb: 47 vs 87 months; stage Ⅲ to Ⅳ: 27 months vs not reach) and the median disease-free survival (DFS) (stage Ⅰ to Ⅱb: 42 vs 78 months; stage Ⅲ to Ⅳ: 18 vs 39 months) of patients with high expression of NETs in stage Ⅰ to II b and stage Ⅲ to Ⅳ were lower than those with low expression (stage Ⅰ to Ⅱb: OS, <i>P</i>＜0.001; DFS, <i>P</i>＜0.001; stage Ⅲ to Ⅳ: OS, <i>P</i>=0.001; DFS, <i>P</i>=0.022). The OS (stage Ⅰ to Ⅱb: <i>HR</i>=3.513, 95% <i>CI:</i> 1.966-6.277, <i>P</i>＜0.001; stage Ⅲ to Ⅳ: <i>HR</i>=3.215, 95% <i>CI:</i> 1.324-7.806, <i>P</i>=0.010) and the DFS (stage Ⅰ to Ⅱb: <i>HR</i>=2.478 ,95% <i>CI:</i> 1.396-4.400, <i>P</i>=0.002; stage Ⅲ to Ⅳ: <i>HR</i>=2.248, 95% <i>CI:</i> 1.089-4.638, <i>P</i>=0.028) in the group with high expression of NETs in either stage Ⅰ to Ⅱb or stage Ⅲ to Ⅳ were significantly shorter than those in the group with low expression. <b>Conclusion:</b> The EGFR wild-type lung adenocarcinoma patients with high expression of NETs have relatively shorter DFS and OS, which are independent risk factors for the prognosis of patients with EGFR wild-type lung adenocarcinoma, and are likely to be the potential biomarkers for the diagnosis and treatment of EGFR wild-type lung adenocarcinoma.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"669-678"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on liquid biopsy-based multi-cancer early detection (2025 edition)].","authors":"W Q Chen, K X Chen, Y T He, W H Jia, Z H Liu, H X Ma, X P Miao, K F Pan, C Wu, C F Xia, J L Xing, Y J Xu","doi":"10.3760/cma.j.cn112152-20250605-00257","DOIUrl":"10.3760/cma.j.cn112152-20250605-00257","url":null,"abstract":"<p><p>Cancer stands as a significant global public health challenge, and cancer screening serves as a pivotal strategy for reducing its mortality. Presently, only a limited number of cancer types have appropriate screening methods available. Traditional single-cancer screening approaches are fraught with limitations, including invasiveness, low accuracy, and poor patient compliance. Multi-cancer early detection (MCED) leveraging liquid biopsy technology enables non-invasive and efficient early detection of multiple cancers by analyzing biomarkers such as cell-free DNA, cell-free RNA, proteins, and metabolites in blood and other bodily fluids. This innovative approach substantially broadens the spectrum of detectable cancers and enhances population coverage, showcasing immense potential for improving existing cancer screening strategies. This expert consensus comprehensively reviews the progress of liquid biopsy-based MCED, biomarker selection and detection technologies, the criteria for cancer type selection, research design and clinical utility evaluation, as well as implementation pathways. The overarching goal of this consensus is to offer scientific guidance for further research and the widespread adoption of MCED, thereby facilitating the continuous optimization of cancer screening strategies.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 7","pages":"558-574"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on whole-course management of prostate cancer (2025 edition)].","authors":"","doi":"10.3760/cma.j.cn112152-20250212-00053","DOIUrl":"10.3760/cma.j.cn112152-20250212-00053","url":null,"abstract":"<p><p>Prostate cancer represents a prevalent malignancy within the male genitourinary system. In recent years, its incidence in China has gradually increased, becoming a significant public health issue. While early detection correlates strongly with improved prognosis, the majority of newly diagnosed prostate cancer patients in China are already in intermediate or advanced stages, precluding curative-intent interventions and contributing to marked survival disparities. The progression of prostate cancer is lengthy, typically encompassing diagnosis, treatment, progression, metastasis, and death, accompanied by a decline in quality of life. Personalized treatment plans should be developed based on the disease stage and patient preferences. In non-metastatic prostate cancer, where the tumor is confined to the prostate, surgery and radiotherapy are the primary treatments, supplemented by neoadjuvant and adjuvant therapies to delay metastasis. For metastatic prostate cancer, systemic therapy is prioritized to prolong survival. In metastatic hormone-sensitive prostate cancer, controlling androgen levels is crucial, while treatment options for metastatic castration resistant prostate cancer are relatively limited, necessitating individualized and precise treatment. During prostate cancer management, prostate-specific antigen levels are closely linked to prognosis and require monitoring. Bone metastasis, the most common site in prostate cancer patients, often triggers skeletal-related events, demanding effective prevention and management. Treatment-related adverse reactions are also a clinical challenge, requiring balanced risk-benefit assessments and judicious drug selection to preserve quality of life. Rapid advancements in screening technologies, surgical innovations, drug development, and China-specific epidemiological factors further complicate decision-making in holistic prostate cancer management. To optimize the standardization of prostate cancer diagnosis and treatment in China, the Genitourinary Oncology Committee of Chinese Anti-cancer Association synthesized global guidelines, clinical evidence and clinical expertise, and addressed critical challenges in the whole-course management of prostate cancer to formulate a multidisciplinary consensus. The expert consensus on whole-course management of prostate cancer (2025 edition) establishes standardized protocols to guide clinical practice, improve treatment outcomes, and enhance patient quality of life.</p>","PeriodicalId":39868,"journal":{"name":"中华肿瘤杂志","volume":"47 ","pages":"617-634"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}